Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin C + mitoxantrone
- Development stage
- Unknown
- Lead developer
- UroGen Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of mitomycin C and mitoxantrone used primarily for the treatment of advanced breast cancer. This combination has shown activity against breast cancer with varying response rates across studies. It is generally associated with mild hematological toxicity and minimal gastrointestinal side effects and alopecia compared to other chemotherapy regimens, though serious adverse events including hemolytic-uremic syndrome, pulmonary fibrosis, and hepatic failure have been reported.
02
Targets
TOP2A (DNA topoisomerase II)DNATOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on mitomycin C + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin C + mitoxantrone.